Formula & Concentration

Immune Globulin (Human)

Manufacturer

Grifols

Indications

Pregnancy and Other Obstetric

Conditions HyperRHO S/D Full Dose is recommended for the prevention of Rh hemolytic disease of the newborn by its administration to the Rho(D) negative mother within 72 hours after birth of an Rho(D) positive infant,(12) providing the following criteria are met:
1. The mother must be Rho(D) negative and must not already be sensitized to the Rho(D) factor.
2. Her child must be Rho(D) positive, and should have a negative direct antiglobulin test (see PRECAUTIONS).

If HyperRHO S/D Full Dose is administered antepartum, it is essential that the mother receive another dose of HyperRHO S/D Full Dose after delivery of an Rho(D) positive infant.

If the father can be determined to be Rho(D) negative, HyperRHO S/D Full Dose need not be given. HyperRHO S/D Full Dose should be administered within 72 hours to all nonimmunized Rho(D) negative women who have undergone spontaneous or induced abortion, following ruptured tubal pregnancy, amniocentesis or abdominal trauma unless the blood group of the fetus or the father is known to be Rho(D) negative.(7,8) If the fetal blood group cannot be determined, one must assume that it is Rho(D) positive,(2) and HyperRHO S/D Full Dose should be administered to the mother.

Transfusion
HyperRHO S/D Full Dose may be used to prevent isoimmunization in Rho(D) negative individuals who have been transfused with Rho(D) positive red blood cells or blood components containing red blood cells.(5,13)

Product Options

Package Size NDC Presentation
1500 IU 13533-0631-02 Syringe

Shelf Life & Storage

36 months

Store at 2–8°C (36–46°F). Do not freeze.

HyperRHO

Order Online

or call

800-304-3064

Can't find what you are looking for?

Please call us and we would love to help.

800-304-3064